Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucrictibant for acute treatment of hereditary angioedema attacks
NCT04618211Phase 2Completed
- Sponsor
- Pharvaris
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Started Feb 2021; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04618211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618211.